UDTR Global Radar

UDTR Global Rights of Nature Radar

Documentary registry of records detected across the scholarly, legal and institutional infrastructures monitored by UDTR.

A global documentary infrastructure designed to achieve the broadest verifiable and scientifically defensible coverage of the Rights of Nature.

← Back to Radar

CCL18: a potential immunosuppressive biomarker for prognosis in ABC diffuse large B-cell lymphoma

Identification

Public canonical key
radar:r-385a391644e36150bce52841ffcd11fa
Authors
Marta Rodríguez · Francisco Rojas-Vega · Jesús Frutos Dıáz-Alejo · Ignacio Mahíllo · Cristina Serrano · Alberto López García · Teresa Morales‐Ruíz · Teresa Roldán‐Arjona · Joaquín Sánchez‐García · Ana Rio‐Machín · Daniel Morillo · María Ángeles Rodríguez Pérez · Raúl Córdoba · Pilar Llamas · Socorro Marıá Rodríguez-Pinilla · Juana Serrano‐López
Reported year
2025
Reported language
en
Source type
article
First detected
2026-11-14T02:15:29.429644+00:00
Last metadata observation
2026-11-14T02:15:29.429644+00:00
Last HTTP verification
Not checked

Institutions reported by the source

Hospital Universitario Fundación Jiménez Díaz · Instituto Maimónides de Investigación Biomédica de Córdoba · Hospital Universitario Reina Sofía · University of Córdoba · Instituto de Investigación Sanitaria Fundación Jiménez Díaz · Universidad Autónoma de Madrid · Queen Mary University of London · Barts Cancer Institute · Universidad Alfonso X el Sabio

Reported affiliation countries

ES · GB

Documentary abstract — original language

Background Activated B-cell (ABC) diffuse large B-cell lymphoma (DLBCL) has worse outcomes than the germinal center B-cell (GCB) subtype, but underlying molecular mechanisms remain poorly understood. Methods Transcriptomic analysis on 43 DLBCL samples (23 GCB and 20 ABC) was performed using NanoString PanCancer Immune Profiling Panel with 30 cell-of-origin genes. Tumor microenvironment characterization was performed using CIBERSORTx and gene set enrichment analysis (GSEA) deconvolution. Based on our previous findings of MAPK10 downregulation in ABC lymphomas, MAPK10 promoter methylation was studied via pyrosequencing. Prognostic biomarkers were identified using the Cox regression and least absolute shrinkage and selection operator (LASSO) regularization. Therapeutic candidates were identified through connectivity mapping. Results ABC lymphomas showed distinct profiles with the overexpression of VTCN1 , CDK4 , and CXCR5 and the downregulation of MMP9 and MAPK10 . GSEA revealed enrichment of inflammatory pathways with immunosuppressive signals in ABC cases. Confirming our prior observations, MAPK10 downregulation in ABC tumors was associated with promoter hypermethylation and inferior overall survival ( p < 0.01). Immune deconvolution revealed greater microenvironmental diversity in ABC cases with significant eosinophil enrichment. High CD8 + T-cell abundance was associated with improved survival, particularly in ABC patients ( p < 0.01). Multivariate analysis identified CCL18 as an independent adverse prognostic factor (HR: 1.87, 95% CI: 1.25–2.79, p < 0.01). Connectivity mapping identified proteasome inhibitors and CDK4/6 inhibitors as promising therapeutic candidates. Conclusions We validated MAPK10 promoter hypermethylation and CCL18 overexpression as prognostic biomarkers in ABC DLBCL. These findings, derived from integrative transcriptomic and immunogenomic profiling, provide clinically relevant insights into disease biology and support biomarker-guided strategies for precision treatment in aggressive B-cell lymphomas.

Identifiers

OPENALEX
https://openalex.org/W4417312536
DOI
10.3389/fimmu.2025.1693730
PMID
https://pubmed.ncbi.nlm.nih.gov/41472741
PMCID
https://www.ncbi.nlm.nih.gov/pmc/articles/12745396

Documentary context

Documentary family
article
Source-reported types
article
Publishers
Frontiers Media

Entity mentions are not evidence of legal recognition. Jurisdiction studied is separate from author affiliation country.

Sources

OpenAlex · Record 1

Cite this reference

Marta Rodríguez; Francisco Rojas-Vega; Jesús Frutos Dıáz-Alejo; Ignacio Mahíllo; Cristina Serrano; Alberto López García; Teresa Morales‐Ruíz; Teresa Roldán‐Arjona; Joaquín Sánchez‐García; Ana Rio‐Machín; Daniel Morillo; María Ángeles Rodríguez Pérez; Raúl Córdoba; Pilar Llamas; Socorro Marıá Rodríguez-Pinilla; Juana Serrano‐López. CCL18: a potential immunosuppressive biomarker for prognosis in ABC diffuse large B-cell lymphoma. 2025. https://doi.org/10.3389/fimmu.2025.1693730

JSON · CSL-JSON · BibTeX · RIS · CSV · JSON-LD ·

APA, Chicago, ISO 690: bibliographic formats using available fields. OSCOLA / Bluebook: structured data only; full legal citation compliance is not claimed without verification of required elements.

APA
Marta Rodríguez; Francisco Rojas-Vega; Jesús Frutos Dıáz-Alejo; Ignacio Mahíllo; Cristina Serrano; Alberto López García; Teresa Morales‐Ruíz; Teresa Roldán‐Arjona; Joaquín Sánchez‐García; Ana Rio‐Machín; Daniel Morillo; María Ángeles Rodríguez Pérez; Raúl Córdoba; Pilar Llamas; Socorro Marıá Rodríguez-Pinilla; Juana Serrano‐López. (2025). CCL18: a potential immunosuppressive biomarker for prognosis in ABC diffuse large B-cell lymphoma. https://doi.org/10.3389/fimmu.2025.1693730
Chicago
Marta Rodríguez; Francisco Rojas-Vega; Jesús Frutos Dıáz-Alejo; Ignacio Mahíllo; Cristina Serrano; Alberto López García; Teresa Morales‐Ruíz; Teresa Roldán‐Arjona; Joaquín Sánchez‐García; Ana Rio‐Machín; Daniel Morillo; María Ángeles Rodríguez Pérez; Raúl Córdoba; Pilar Llamas; Socorro Marıá Rodríguez-Pinilla; Juana Serrano‐López. CCL18: a potential immunosuppressive biomarker for prognosis in ABC diffuse large B-cell lymphoma. 2025. https://doi.org/10.3389/fimmu.2025.1693730
ISO 690
Marta Rodríguez; Francisco Rojas-Vega; Jesús Frutos Dıáz-Alejo; Ignacio Mahíllo; Cristina Serrano; Alberto López García; Teresa Morales‐Ruíz; Teresa Roldán‐Arjona; Joaquín Sánchez‐García; Ana Rio‐Machín; Daniel Morillo; María Ángeles Rodríguez Pérez; Raúl Córdoba; Pilar Llamas; Socorro Marıá Rodríguez-Pinilla; Juana Serrano‐López. CCL18: a potential immunosuppressive biomarker for prognosis in ABC diffuse large B-cell lymphoma. 2025. https://doi.org/10.3389/fimmu.2025.1693730

Warning: Undefined array key "last_link_verified" in /home/clients/e27d81e12f04d2bfd747aa264540ac56/sites/_UDTR_APP/legal_library_reference.php on line 31

UDTR Global Rights of Nature Legal Library. CCL18: a potential immunosuppressive biomarker for prognosis in ABC diffuse large B-cell lymphoma. Documentary record: https://www.declarationuniverselledesdroitsdelarbre.org/global-rights-of-nature-radar/reference/r-385a391644e36150bce52841ffcd11fa/ · Last HTTP verification: not performed

Report a correction

Frozen-version metadata

Research dossiers and documentary relations

Source roles

Bibliographic / original publication source · https://doi.org/10.3389/fimmu.2025.1693730

An authority link alone does not verify a legal claim. Abstracts and full texts remain subject to their source terms.

Documentary status

Relevance pending

Library

This identity is not yet included in the Legal Library.

UDTR Global Rights of Nature Legal Library